ExoCoBio
Developing innovative therapeutics as well as cosmetic products based on stem cell-derived exosomes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
$9.3m Valuation: $135m | Series C | ||
| Total Funding | 000k | ||
Related Content
ExoCoBio, Inc. operates as a biopharmaceutical company with a focus on exosome-based technologies for aesthetic and therapeutic applications. Founded in 2017 by Byong Cho, the company has positioned itself at the forefront of the regenerative aesthetics market. Cho's background includes a Ph.D. in Molecular Biology from the University of Illinois at Urbana-Champaign and extensive experience in the pharmaceutical industry, including roles at Takeda Pharmaceutical and Green Cross Corp. This deep scientific and corporate expertise has been pivotal in guiding ExoCoBio's strategic direction and research initiatives.
The company's core business revolves around the research, development, and commercialization of exosomes, which are nanoscale vesicles secreted by cells that play a crucial role in cell-to-cell communication. ExoCoBio has developed a proprietary technology called ExoSCRT™, which is designed to isolate and purify high-quality exosomes from stem cells. This technology underpins their product lines, which are primarily aimed at the cosmetic and dermatological markets. The business model appears to be centered on selling these exosome-based products to professionals in the aesthetics field, such as dermatology clinics and skincare specialists.
ExoCoBio's product portfolio includes several lines, such as ASCE+, EXO'V E, and Celltrix. The ASCE+ line, for instance, offers lyophilized exosomes intended for skin rejuvenation, demonstrating benefits such as inflammation relief, skin barrier improvement, and collagen synthesis stimulation. These products are marketed for professional use, leveraging the regenerative capabilities of exosomes to address various skin concerns. The company has also expanded into the biopharmaceutical space, exploring therapeutic applications for exosomes in treating conditions like atopic dermatitis and inflammatory diseases, with some candidates entering preclinical stages. To support its global reach, ExoCoBio has established a significant international presence, exporting its aesthetic products to over 70 countries and setting up subsidiaries in markets like Japan and Indonesia.
Keywords: exosome technology, regenerative aesthetics, biopharmaceuticals, skincare, dermatology, stem cells, ASCE+, ExoSCRT, atopic dermatitis, cosmeceuticals